Gattex sales chugging along for NPS in 2Q
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals has all of its trains running on schedule with Gattex (teduglutide) on track to beat previous estimates by the end of the year, preparations for ex-US sales under way, and plans for a Natpara biologics license application (BLA) filing in the US before the end of 2013.